Actively Recruiting
Cardiac Magnetic Resonance for Risk Stratification in Non-dilated Left Ventricular Cardiomyopathy
Led by Chinese Academy of Medical Sciences, Fuwai Hospital · Updated on 2026-01-21
1000
Participants Needed
1
Research Sites
1095 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Non-dilated left ventricular cardiomyopathy (NDLVC), a newly defined cardiomyopathy subtype characterized by non-ischemic myocardial abnormalities without left ventricular dilation, poses challenges in prognosis assessment and risk stratification. This is a retrospective observational study aiming to explore the prognostic value of cardiac magnetic resonance (CMR) findings and identify key risk factors for adverse cardiovascular outcomes in patients with NDLVC. We will retrospectively enroll patients diagnosed with NDLVC who underwent CMR examination at the study institution during the predefined study period. CMR parameters, including left ventricular ejection fraction (LVEF), late gadolinium enhancement (LGE) patterns, myocardial strain, and the extent of myocardial fibrosis or fatty replacement, will be extracted and analyzed. The primary endpoint is a composite of major adverse cardiovascular events (MACE), including all-cause mortality, heart transplantation, or left ventricular assist device (LVAD) implantation. The study intends to clarify the association between specific CMR features and long-term prognosis in NDLVC patients, thereby establishing a CMR-based risk stratification strategy to guide clinical decision-making and improve patient outcomes. Given the retrospective nature, data will be collected from electronic medical records and CMR databases, with ethical approval obtained prior to study initiation.
CONDITIONS
Official Title
Cardiac Magnetic Resonance for Risk Stratification in Non-dilated Left Ventricular Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 16 years or older
- Indexed left ventricular end-diastolic volume less than 96 mL/m2 for females and less than 105 mL/m2 for males at baseline cardiac magnetic resonance
- Left ventricular ejection fraction below 50% and/or presence of non-ischemic left ventricular scar or fatty replacement on baseline cardiac magnetic resonance
You will not qualify if you...
- No enhanced cardiac magnetic resonance images due to contraindications for gadolinium contrast, such as severe kidney disease
- Ischemic heart disease defined by over 50% stenosis in a major coronary artery, ischemic late gadolinium enhancement pattern, or prior coronary revascularization
- Moderate to severe valvular heart disease, congenital heart disease, or uncontrolled hypertension
- Systemic rheumatologic diseases or sarcoidosis
- Diagnostic criteria meeting other cardiomyopathies as defined by the European Society of Cardiology
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital
Beijing, China, 100037
Actively Recruiting
Research Team
L
Lu Minjie PHD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here